Immuneering (IMRX) vs Lifecore Biomedical (LFCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Lifecore Biomedical (LFCR) has outperformed Immuneering (IMRX) over the past year, losing 4.5% versus a loss of 36.8%. Over five years, LFCR leads with a -34.4% price change compared with -84.5% for IMRX. Lifecore Biomedical is the larger company by market cap ($243.9 million vs $238.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMRX | LFCR |
|---|---|---|
| Share price | $3.68 | $6.44 |
| Market cap | $238.09M | $243.92M |
| 1-day change | -4.66% | -0.08% |
| YTD return | -41.34% | -21.27% |
| 1-year return | -36.82% | -4.45% |
| 5-year return | -84.47% | -34.35% |
| EPS (TTM) | $-0.93 | $-1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.48 | $8.98 |
| 52-week low | $3.60 | $3.63 |
| Distance from 52-week high | -56.60% | -28.34% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +366.58% | -2.41% |
| Average volume | 694.54K | 289.19K |
| Shares outstanding | 64.70M | 37.91M |
| Employees | 57 | 382 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LFCR has outperformed IMRX by 32.4 percentage points over the past year.
About Immuneering
IMRX stock →Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
About Lifecore Biomedical
LFCR stock →Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities.
Health Care · Biotechnology: Pharmaceutical Preparations · 382 employees
IMRX vs LFCR FAQ
Which is bigger, Immuneering or Lifecore Biomedical?
Lifecore Biomedical (LFCR) is larger, with a market capitalization of $243.92M compared with $238.09M for Immuneering (IMRX).
Which stock has performed better over the past year, IMRX or LFCR?
LFCR returned -4.45% over the past 12 months, compared with -36.82% for IMRX (price return, excluding dividends). Past performance does not predict future results.
Are Immuneering and Lifecore Biomedical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.